Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Gilteritinib +1 More for Acute Myelogenous Leukemia
Recruiting1 awardPhase 1
Columbus, Ohio
This trial is testing the safety and effectiveness of combining two medications, SNDX-5613 and gilteritinib, to treat patients with a specific type of leukemia. The leukemia has either come back
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.